Claire Mazumdar, Ph.D., serves as Co-Founder and Chief Executive Officer of Bicara Therapeutics Inc., a biotechnology company developing next-generation tumor-targeted therapies for solid tumors. Holding a Ph.D. in Tumor Biology from The Rockefeller University, Dr. Mazumdar completed her postdoctoral training at Memorial Sloan Kettering Cancer Center, where she honed her expertise in cancer immunology and signaling pathways. Prior to Bicara, she spent over a decade at Regeneron Pharmaceuticals, rising to Executive Director of Oncology Research, where she led cross-functional teams in discovering and advancing novel antibody-based therapies targeting key oncogenic drivers. Under Dr. Mazumdar's visionary leadership, Bicara has rapidly progressed its proprietary bifunctional antibody platform, with lead candidate ficerafusp alfa—a first-in-class EGFR/TGFβ trap—entering Phase 1/2 clinical trials for head and neck squamous cell carcinoma and expanding into frontline settings. The company secured more than $400 million in financing across Series A and B rounds, fueling platform expansion and manufacturing scale-up. In 2023, Bicara's groundbreaking work culminated in its acquisition by Merck for up to $1.7 billion, validating Dr. Mazumdar's strategic focus on precision immunology to transform outcomes for patients with difficult-to-treat cancers.